COVID-19 and the potential long-term impact on antimicrobial resistance

Timothy M. Rawson, Luke S.P. Moore, Enrique Castro-Sanchez, Esmita Charani, Frances Davies, Giovanni Satta, Matthew Ellington, Alison H. Holmes*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

226 Citations (Scopus)

Abstract

The emergence of the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) has required an unprecedented response to control the spread of the infection and protect the most vulnerable within society. Whilst the pandemic has focused society on the threat of emerging infections and hand hygiene, certain infection control and antimicrobial stewardship policies may have to be relaxed. It is unclear whether the unintended consequences of these changes will have a net-positive or -negative impact on rates of antimicrobial resistance. Whilst the urgent focus must be on controlling this pandemic, sustained efforts to address the longer-term global threat of antimicrobial resistance should not be overlooked.

Original languageEnglish
Pages (from-to)1681-1684
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume75
Issue number7
Early online date20 May 2020
DOIs
Publication statusPublished - 1 Jul 2020

Bibliographical note

Funding Information: L.S.P.M. reports personal fees from bioMérieux, personal fees from DNAelectronics, personal fees from Dairy Crest, personal fees from Profile Pharma, grants and personal fees from Pfizer, grants from Leo Pharma, grants from CW+ charity. M.J.E. is a member of PHE’s AMRHAI Reference lab which has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc., Allecra Therapeutics, Amplex, AstraZeneca UK Ltd, AusDiagnostics, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, ECDC, Food Standards Agency, GlaxoSmithKline Services Ltd, Helperby Therapeutics, Henry Stewart Talks, IHMA Ltd, Innovate UK, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharma Co., Ltd, Mobidiag, Momentum Biosciences Ltd, Neem Biotech, NIHR, Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Shionogi & Co. Ltd, Trius Therapeutics, VenatoRx Pharmaceuticals, Wockhardt Ltd and WHO. E.C-S. is an NIHR Senior Nurse and Midwife Research Leader, and acknowledges the support of the NIHR Biomedical Research Centre.

Open Access: Free to read, but no Open Access licence.

Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.

Citation: Timothy M Rawson, Luke S P Moore, Enrique Castro-Sanchez, Esmita Charani, Frances Davies, Giovanni Satta, Matthew J Ellington, Alison H Holmes, COVID-19 and the potential long-term impact on antimicrobial resistance, Journal of Antimicrobial Chemotherapy, Volume 75, Issue 7, July 2020, Pages 1681–1684,

DOI: https://doi.org/10.1093/jac/dkaa194

Fingerprint

Dive into the research topics of 'COVID-19 and the potential long-term impact on antimicrobial resistance'. Together they form a unique fingerprint.

Cite this